Literature DB >> 10534556

Articular hypermobility in Icelandic 12-year-olds.

A Qvindesland1, H Jónsson.   

Abstract

OBJECTIVE: To examine the prevalence of articular hypermobility and its relationship to musculoskeletal pain in Icelandic 12-yr-olds, and to obtain baseline data for a prospective study on the subject.
METHODS: A total of 267 12-yr-olds were examined for articular hypermobility by the Beighton criteria. The children also answered a questionnaire concerning musculoskeletal pain and injuries, sports and musical activity.
RESULTS: The prevalence of hypermobility (defined as >/=4 Beighton criteria) was 40.5% in girls and 12.9% in boys. Despite slight trends for hypermobile subjects to be less active in sports and to report more joint pain, no correlation could be found between hypermobility and musculoskeletal symptoms.
CONCLUSIONS: An unusually marked sex difference in hypermobility exists among Icelandic 12-yr-olds, but hypermobility does not seem to affect joint symptoms or leisure activities at this age.

Entities:  

Mesh:

Year:  1999        PMID: 10534556     DOI: 10.1093/rheumatology/38.10.1014

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  13 in total

1.  Relationship of Q angle and joint hypermobility and Q angle values in different positions.

Authors:  Omer Faruk Sendur; Gulcan Gurer; Tuncay Yildirim; Emine Ozturk; Ali Aydeniz
Journal:  Clin Rheumatol       Date:  2005-10-06       Impact factor: 2.980

2.  Is joint hypermobility important in prepubertal children?

Authors:  Pelin Yazgan; Iclal Geyikli; Dost Zeyrek; Lutfu Baktiroglu; Mehmet Ali Kurcer
Journal:  Rheumatol Int       Date:  2008-01-18       Impact factor: 2.631

3.  Pain intensity and quality of life perception in children with hypermobility syndrome.

Authors:  Francis Fatoye; Shea Palmer; Fiona Macmillan; Philip Rowe; Marietta van der Linden
Journal:  Rheumatol Int       Date:  2011-01-26       Impact factor: 2.631

4.  High hand joint mobility is associated with radiological CMC1 osteoarthritis: the AGES-Reykjavik study.

Authors:  H Jónsson; G J Elíasson; A Jónsson; G Eiríksdóttir; S Sigurdsson; T Aspelund; T B Harris; V Gudnason
Journal:  Osteoarthritis Cartilage       Date:  2008-10-17       Impact factor: 6.576

5.  Epidemiology of generalized joint laxity (hypermobility) in fourteen-year-old children from the UK: a population-based evaluation.

Authors:  Jacqui Clinch; Kevin Deere; Adrian Sayers; Shea Palmer; Chris Riddoch; Jonathan H Tobias; Emma M Clark
Journal:  Arthritis Rheum       Date:  2011-09

6.  Joint hypermobility in children with idiopathic scoliosis: SOSORT award 2011 winner.

Authors:  Dariusz Czaprowski; Tomasz Kotwicki; Paulina Pawłowska; Lukasz Stoliński
Journal:  Scoliosis       Date:  2011-10-07

7.  EPIDEMIOLOGY OF MUSCULOSKELETAL DISORDERS IN PRIMARY SCHOOL CHILDREN IN BOSNIA AND HERZEGOVINA.

Authors:  Selma Azabagic; Razija Spahic; Nurka Pranjic; Maida Mulic
Journal:  Mater Sociomed       Date:  2016-06-01

8.  The effectiveness of a multidisciplinary intervention strategy for the treatment of symptomatic joint hypermobility in childhood: a randomised, single Centre parallel group trial (The Bendy Study).

Authors:  Peter Bale; Vicky Easton; Holly Bacon; Emma Jerman; Laura Watts; Garry Barton; Allan Clark; Kate Armon; Alex J MacGregor
Journal:  Pediatr Rheumatol Online J       Date:  2019-01-08       Impact factor: 3.054

9.  Risk factors for development of non-specific musculoskeletal pain in preteens and early adolescents: a prospective 1-year follow-up study.

Authors:  Ashraf El-Metwally; Jouko J Salminen; Anssi Auvinen; Gary Macfarlane; Marja Mikkelsson
Journal:  BMC Musculoskelet Disord       Date:  2007-05-23       Impact factor: 2.362

10.  Generalized joint hypermobility in childhood is a possible risk for the development of joint pain in adolescence: a cohort study.

Authors:  Oline Sohrbeck-Nøhr; Jens Halkjær Kristensen; Eleanor Boyle; Lars Remvig; Birgit Juul-Kristensen
Journal:  BMC Pediatr       Date:  2014-12-10       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.